CAR T-cell therapy is a groundbreaking cancer treatment that involves genetically modifying a patient's T-cells to target and destroy cancer cells. Initially used for blood cancers like leukemia and lymphoma, it has expanded to other cancers with significant success. Eurofins Viracor supports this therapy with its ExPeCT™ anti-CD19 CAR T-cell assay, which monitors the expansion and persistence of CAR T-cells, optimizing patient outcomes and ensuring safety. As research advances, CAR T-cell therapy continues to offer promising potential for more widespread cancer treatment.
